Efficacy of Dual PD-1/PD-L1 and CTLA-4 Inhibitors in Advanced NSCLC: A Meta-Analysis

A meta-analysis of randomized controlled trials published up to August 2025, evaluating dual immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. The dataset includes results from 10 RCTs comprising 6,369 patients, with primary outcomes of overall survival and progression-free survival. It was authored by Tianfu Dai and published on figshare in May 2026.

Use Cases

• Evaluate overall survival benefit of dual PD-1/PD-L1 and CTLA-4 inhibitors based on hazard ratios from RCTs.
• Identify patient subgroups that benefit most from dual immunotherapy based on characteristics like PD-L1 expression, TMB, and smoking status.
• Assess progression-free survival outcomes for dual ICI therapy compared to control treatments like chemotherapy or monotherapy.

Strengths

• Data is derived from 10 randomized controlled trials, a gold-standard study design.
• Analysis includes a substantial patient population of 6,369 individuals.
• Results are stratified by multiple clinically relevant subgroups (e.g., histology, PD-L1 TPS, TMB, metastasis sites).

Limitations

• The dataset is a 20.0 KB DOCX file, suggesting it contains summary-level meta-analysis results rather than patient-level data.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for certain analyses.

Provenance

Source

Systematic review of RCTs from Cochrane Library, Embase, Web of Science, and PubMed.

Collection Method

Meta-analysis of randomized controlled trials.

Time Range

Trials from database inception to August 2025.

Freshness

Last updated 2026-05-11 05:31:07; freshness should be verified.